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Summary
Dietary nutrient limitation (dietary restriction) is
known to increase lifespan in a variety of organisms.
Although the molecular events that couple dietary
restriction to increased lifespan are not clear, studies
of the model eukaryote Saccharomyces cerevisiae
have implicated several nutrient-sensitive kinases,
including the target of rapamycin complex 1 (TORC1),
Sch9, protein kinase A (PKA) and Rim15. We have
recently demonstrated that TORC1 activates Sch9 by
direct phosphorylation. We now show that Sch9
inhibits Rim15 also by direct phosphorylation. Treat-
ment of yeast cells with the speciﬁc TORC1 inhibitor
rapamycin or caffeine releases Rim15 from TORC1-
Sch9-mediated inhibition and consequently increases
lifespan. This kinase cascade appears to have been
evolutionarily conserved, suggesting that caffeine
may extend lifespan in other eukaryotes, including
man.
Introduction
Reduction of food intake, commonly referred to as dietary
restriction (DR), has been shown to slow ageing and
extend lifespan in virtually every biological system exam-
ined (Masoro, 2005). However, the underlying mecha-
nisms that couple DR to lifespan extension remain poorly
deﬁned. Recently, the relatively simple eukaryote Saccha-
romyces cerevisiae (bakers’ yeast) has emerged as a
powerfulmodel system to study the genetic and physiologi-
cal factors that alter lifespan. Studies in yeast have dem-
onstrated that genetic impairment of conserved nutrient-
responsive signal transduction pathways can phenocopy
DR and extend both chronological lifespan (CLS; viability
in stationary phase) and replicative lifespan (RLS; number
of daughters/buds produced). Speciﬁcally, reducing the
kinase activities of the target of rapamycin complex 1
(TORC1), the TORC1 substrate Sch9 or protein kinase A
(PKA) have been found to extend CLS (Fabrizio et al.,
2001; Longo and Finch, 2003; Kaeberlein et al., 2005;
Powers et al., 2006; Urban et al., 2007). In contrast, reduc-
ing the kinase activity of Rim15 decreases CLS (Reinders
et al., 1998; Fabrizio et al., 2001; Wei et al., 2008). Impor-
tantly, RLS is not further extended byDR inTORC1or Sch9
mutants, strongly suggesting that DR extends RLS via
TORC1-Sch9 (Kaeberlein et al., 2005). TORC1-Sch9 and
PKAare thought to signal in parallel pathways to positively
regulate glycolysis, ribosome biogenesis and growth (Jor-
gensen et al., 2004). Additionally, TORC1-Sch9 and PKA
signals converge at Rim15 to inhibit stress responses, G0
programmes, CLS and, as recently reported, also autoph-
agy (Reinders et al., 1998; Pedruzzi et al., 2003; Wanke
et al., 2005; Yorimitsu et al., 2007). Notably, PKA inhibits
the kinase activity of Rim15 by direct phosphorylation
(Reinders et al., 1998), while TORC1 contributes to the
cytoplasmic sequestration of Rim15 via partially character-
izedmechanism(s) (Wanke et al., 2005). Rim15 appears to
be conserved among eukaryotes as it shares homology
with the mammalian serine/threonine kinase large tumour
suppressor (LATS) (Pedruzzi et al., 2003; Cameroni et al.,
2004); TORC1, Sch9 and PKA have clear orthologues in
mammals –mammalianTORC1 (mTORC1), S6K andPKA
respectively (Powers, 2007).
Yeast andmammalianTOR (mTOR) belong to a family of
related kinases known as phosphytidylinositol kinase-
related kinases (PIKKs). In mammals, this family also
includes DNA-dependent protein kinase catalytic subunit
(DNA-PKcs), ataxia telangiectasia mutated (ATM) and
ATMandRad3-related (ATR) kinases. The catalytic activity
of these PIKKs can be inhibited to varying degrees by a
number of pharmacological agents, including the xanthine
alkaloid caffeine. Curiously, although caffeine inhibits
multiple PIKKs in vitro (Sarkaria et al., 1999; Block et al.,
2004), it appears to preferentially inhibit mTOR over other
PIKKs in vivo (Cortez, 2003; Kaufmann et al., 2003). In
contrast, the macrocyclic lactone rapamycin is a potent
and speciﬁc inhibitor of TORC1/mTORC1 (Wullschleger
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et al., 2006). Clinically, rapamycin is used as an immuno-
suppressant and is presently being evaluated as an anti-
tumour agent (Guertin and Sabatini, 2007). Of relevance to
this study is the ﬁnding that low concentrations of rapamy-
cin signiﬁcantly extend CLS in yeast (Powers et al., 2006).
Caffeine has been proposed to target many cellular
activities with cAMP phosphodiesterase being perhaps
the most famous target (Bode and Dong, 2007). However,
the notion that caffeine inhibits cAMP phosphodiesterase
is controversial. Indeed, recent studies in yeast (Kuranda
et al., 2006; Reinke et al., 2006) have demonstrated that
TORC1, and not cAMP phosphodiesterase, is a major
target of caffeine. Using both genetic and biochemical
approaches to build on these recent results, we conﬁrm
that TORC1, and not TORC2, is the growth-limiting target
of caffeine in yeast. Consistently, like low doses of rapa-
mycin, low doses of caffeine signiﬁcantly extended CLS.
Characterization of the pathways downstream of TORC1
revealed that partial loss of TORC1 activity increases
CLS via a previously undescribed TORC1–Sch9–Rim15
kinase cascade. This cascade is structurally conserved
and this may explain recent epidemiological studies,
which correlated moderate coffee (caffeine) consumption
with decreased relative risk of mortality in humans (Fortes
et al., 2000; Paganini-Hill et al., 2007).
Results and discussion
Caffeine inhibits TORC1
To extend the observations that caffeine preferentially
inhibits (m)TOR over other PIKKs in vivo, we asked
whether caffeine inhibits TORC1 and/or the structurally
and functionally distinct TORC2 in yeast (De Virgilio and
Loewith, 2006). Like rapamycin, caffeine caused rapid,
dose-dependent dephosphorylation of the C-terminal
phosphorylation sites in Sch9, whereas partial dephospho-
rylation of the TORC2 substrates Ypk1/2 was observed at
only the highest doses tested (Fig. 1Aand B) (Urban et al.,
2007). This demonstrates that in vivo, TORC1 is more
sensitive to caffeine than TORC2. To determine whether
TORC1 is a primary target of caffeine in yeast, we took
Fig. 1. Caffeine inhibits TORC1.
A. As indicated, yeast cultures were treated
for 15 min with drug vehicle or varying
concentrations of rapamycin or caffeine.
Western blots detecting the extent of Sch9
phosphorylation were used to quantify TORC1
activity in vivo.
B. Similar to A, western blots using antiserum
that recognizes Sch9 and Ypk1/Ypk2 when
phosphorylated at the TORC1 and TORC2
sites respectively were used to quantify
TORC1 and TORC2 activities in vivo following
rapamycin or caffeine treatment (* denotes
signal from an unknown protein that
cross-reacts with the antiserum).
C. Yeast cells can be genetically engineered
to bypass the essential functions of TORC1
and/or TORC2. Spotting 10-fold dilutions
of these cells onto YPD plates containing
drug vehicle, 200 nM rapamycin or 20 mM
caffeine indicates that unlike TORC1 bypass
(TB105-3b + pJU948 + YCplac33 + pRS414),
TORC2 bypass [RL276-2d +
YEp352(YPK2D239A-HA)] confers no resistance
to either of these compounds.
D and E. In vitro TORC1 kinase assays using
Sch9 as substrate were used to determine the
IC50 of caffeine (D) and rapamycin (E). All
assay points in (D) and (E) were done in
triplicate and expressed as mean + SD.
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advantage of our ability to genetically bypass the essential
function of TORC1 in vivo (see Experimental procedures)
(Urban et al., 2007). Bypass of TORC1, but not bypass of
TORC2, renders cells resistant to high doses of rapamycin
and caffeine (Fig. 1C). Consistent with these in vivo data
and in very good agreement with previous reports
(Sarkaria et al., 1999; Reinke et al., 2006), we also
observed that caffeine inhibited TORC1 activity towards its
physiological substrate Sch9 in vitro with an apparent IC50
of 0.22 mM (Fig. 1D; IC50 for rapamycin = 5.2 nM; Fig. 1E).
We infer from these results that TORC1 is the major
growth-limiting target of caffeine in yeast.
The TORC1 target Sch9 directly inhibits Rim15 function
As both TORC1 inhibition (by rapamycin or caffeine) and
loss of Sch9 induce Rim15-dependent gene expression
(Fig. 2A and B; Pedruzzi et al., 2003; Wanke et al., 2005),
we investigated if TORC1 might inhibit Rim15 function
via Sch9. We found that Sch9 physically interacted
with Rim15 in co-immunoprecipitation (co-IP) experiments
(Fig. 3A). Moreover, Sch9, and even more efficiently
Sch93E and Sch92D3E (versions of Sch9 in which residues
phosphorylated by TORC1 have been substituted with
acidic amino acids; Urban et al., 2007), but not kinase-
inactive Sch9KD, phosphorylated Rim15 in vitro within a
loop (Rim15KI) that is inserted between kinase subdomains
VII andVIII (Fig. 3B). This kinase insert is typical of proteins
of the LATS kinase family (Tamaskovic et al., 2003; Cam-
eroni et al., 2004). Mass spectroscopy combined with spe-
ciﬁc Ser to Ala mutation analysis identiﬁed Ser1061 as the
main residue phosphorylated in vitro by Sch9 (Fig. 3C). To
determine whether this amino acid residue is also a target
of Sch9 within cells, we raised an antiserum speciﬁc to this
phosphorylated sequence (Fig. 3D and E). Using this spe-
ciﬁc anti-pSer1061 antiserum,we found that phosphorylation
of Ser1061 in Rim15 in vivo depends largely on the presence
of Sch9 (Fig. 3F), and is highly sensitive to rapamycin and
caffeine treatment (Fig. 3G), as well as to glucose limita-
tion (Fig. 3H). Importantly, dephosphorylation of Ser1061 in
Rim15 induced by rapamycin or caffeine was not observed
in cells expressing the TORC1-independent Sch92D3E
(Fig. 3G). Thus, TORC1 regulates the phosphorylation of
Ser1061 in Rim15 via Sch9.
Next, we wished to determine if phosphorylation of
Ser1061 is physiologically important for Rim15 regulation.
Mutation of Ser1061 to Ala signiﬁcantly and constitutively
impaired cytoplasmic retention of Rim15 (Fig. 4A and B),
which per se was insufficient to activate Rim15-
dependent readouts in exponentially growing cells (as
determined by SSA3 expression and glycogen staining;
Fig. 4C and data not shown). Rapamycin or caffeine treat-
ment caused both nuclear translocation and activation of
Rim15; and expression of Sch92D3E signiﬁcantly blocked
these effects in wild-type, but not in Rim15S1061A-
expressing cells (Fig. 4A–C). Together, these data show
that Ser1061 in Rim15 is a physiologically relevant Sch9
target, and indicate that induction of the Rim15-
dependent programme requires downregulation of Sch9
(to allow accumulation of Rim15 in the nucleus) as well as
alteration of at least one additional Sch9-independent, yet
TORC1-controlled mechanism (to allow activation of the
Rim15-dependent G0 programme).
How does Ser1061 phosphorylation regulate the subcel-
lular localization of Rim15? We previously reported that
the phosphorylation status of Thr1075 contributes to Rim15
cytoplasmic anchorage by 14-3-3 proteins (Wanke et al.,
2005). Thr1075 phosphorylation is independently regulated
by the cyclin-cyclin-dependent kinase Pho80-Pho85
(by direct phosphorylation) and by TORC1 (not through
Pho80-Pho85, but presumably via inhibition of a protein
phosphatase) (Wanke et al., 2005). Given the proximity
between the Thr1075 residue and the newly identiﬁed Sch9
target residue Ser1061, Rim15 likely engages in binding the
two monomeric subunits within a single 14-3-3 protein
dimer (as is typically the case for other proteins). Accord-
ingly, phosphorylation of Ser1061 and Thr1075 in Rim15 may
cooperatively mediate tandem 14-3-3 binding to guaran-
Fig. 2. Rim15 is required for induction of GRE1, SSA3, HSP12
and HSP26 following TORC1 inactivation by rapamycin (A) or
caffeine (B).
A and B. RNA was collected from exponentially growing
(OD600 < 0.8) wild-type (TS120-2d + pJU450 + pJU675) and
isogenic rim15D (RL267-10d + pJU450 + pRS416) mutant cells
following treatment with rapamycin (0.2 mg ml-1) or caffeine (20 mM)
for the times indicated. Equal amounts of RNAs (10 mg) were
probed and the corresponding Northern analyses of indicated
messages are shown.
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tee optimal sequestration of Rim15 in the cytoplasm.
In line with this model, individual Ser1061 or Thr1075 to Ala
mutations in Rim15 signiﬁcantly and constitutively
impaired cytoplasmic retention of Rim15 (Fig. 4A; Wanke
et al., 2005). Moreover, as expected, if TORC1 targets
Ser1061 and Thr1075 by different mechanisms, TORC1 inhi-
bition (using caffeine or rapamycin) exacerbated the cyto-
plasmic retention defects of the Ala variants of both
Rim15-Ser1061 and Rim15-Thr1075 (Fig. 4A and data not
shown; Wanke et al., 2005).
Caffeine extends yeast lifespan via a
TORC1–Sch9–Rim15 kinase cascade
Rim15 orchestrates various physiological processes,
including antioxidant defence mechanisms, accumulation
of storage carbohydrates (such as glycogen) and upregu-
lation of stress-responsive gene expression, all of which
have been shown to critically affect CLS (Reinders et al.,
1998; Fabrizio and Longo, 2003; Pedruzzi et al., 2003;
Cameroni et al., 2004; Powers et al., 2006). This suggests
Fig. 3. Sch9 targets Rim15 both in vitro and in vivo.
A. Sch9 and Rim15 physically interact. Sch9-HA2 (lanes 1 and 3) and Mpk1-HA2 (lane 2; negative control) were immuno-precipitated from
cells coexpressing Rim15-myc13 (lanes 1 and 2) or Ego1-myc13 (lane 3; negative control). Cell lysates (input) and immunoprecipitates (IP)
were subjected to SDS-PAGE and immunoblots were probed using anti-HA or anti-myc antibodies (* denotes detection of the heavy chain of
the immunoprecipitation antibody).
B. Sch9, Sch93E and Sch92D3E, but not inactive Sch9KD, phosphorylate a bacterially expressed, GST-Rim15 kinase insert domain (GST-Rim15KI)
in vitro.
C. Sch9 targets Ser1061 in Rim15. Substitution of Ser1061 with Ala abolishes phosphorylation of GST-Rim15sKI-S1061A by Sch92D3E (sKI harbours
amino acids 1049–1078 of the original Rim15 sequence).
D and E. Phospho-speciﬁc antibodies directed towards Ser1061 in Rim15 recognize GST-Rim15 puriﬁed from exponentially growing yeast prior
to, but not following, phosphatase treatment (D), and bacterially expressed GST-Rim15KI following, but not prior to, in vitro phosphorylation by
Sch9 (and/or Sch93E/Sch92D3E; E). PPI denotes phosphatase inhibitor.
F–H. In vivo phosphorylation of Ser1061 in Rim15 requires the presence of Sch9 (F) and is sensitive to rapamycin (200 nM) or caffeine (20 mM)
treatment (G), and glucose limitation (H).
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that TORC1-Sch9 may negatively regulate CLS mainly
by activating Sch9 and consequently inhibiting Rim15
function. In support of this assumption, expression of
Sch92D3E, similar to loss of Rim15, reduced CLS, while
expression of Rim15S1061A extended CLS in both wild-type
and Sch92D3E-expressing cells (Fig. 5A). Finally, inhibition
of TORC1 by low doses of caffeine (0.2–0.4 mM) or rapa-
mycin (0.55 nM) signiﬁcantly extended CLS in wild-type
[i.e. the median survival of wild-type cells was increased
on average by 0.86 (0.26 SEM; n = 11) or 1.71
(0.36 SEM.; n = 4) days respectively], but not in rim15D
cells (Fig. 5B). At these concentrations of caffeine and
rapamycin, TORC1 activity is reduced by approximately
3% (as interpolated from the results presented in Fig. 1A).
Based on these data, we propose that extension of
lifespan following TORC1 downregulation either physi-
ologically (i.e. DR) or pharmacologically (e.g. using caf-
feine or rapamycin) is mediated by this newly identiﬁed
Sch9-Rim15 effector branch.
Can caffeine extend lifespan in humans?
TORC1, Sch9 and Rim15 are conserved in higher eukary-
otes – mTORC1, S6K and LATS kinases respectively in
humans (Cameroni et al., 2004; Wullschleger et al., 2006;
Urban et al., 2007); and S6K is a well-documented sub-
strate of mTORC1 (Wullschleger et al., 2006). Thus, it is
possible that an analogous mTORC1/S6K/LATS kinase
cascade may also inﬂuence longevity in metazoans.
Indeed, several studies have already demonstrated that
decreased TOR or S6K activity increases lifespan in
worms and ﬂies (Vellai et al., 2003; Jia et al., 2004;
Kapahi et al., 2004). This begs the question: can caffeine
extend lifespan in humans? Caffeine is the most widely
used psychoactive drug worldwide with coffee being the
main source of caffeine in the Western diet. Tantalizingly,
epidemiological studies have correlated habitual coffee
consumption with a decreased relative risk of mortality
(Fortes et al., 2000; Paganini-Hill et al., 2007). Drinking
one cup of coffee results in an approximate peak plasma
concentration of 1–10 mM caffeine in humans (with an
Fig. 4. The TORC1-Sch9 effector branch antagonizes the G0
programme by promoting nuclear exclusion of Rim15.
A. Exponentially growing rim15D cells expressing kinase inactive
GFP-Rim15KD or GFP-Rim15KD/S1061A and either wild-type Sch9, or
Sch92D3E, were treated for 30 min with rapamycin (200 nM; RAP)
or the indicated concentrations of caffeine (in mM; CAF) and
subsequently visualized by ﬂuorescence microscopy.
B. Exponentially growing rim15D cells expressing GFP-Rim15KD or
GFP-Rim15KD/S1061A and either wild-type Sch9 or Sch92D3E, were
treated for 30 min with caffeine (5 mM; CAF) and subsequently
visualized by ﬂuorescence microscopy.
C. Induction of SSA3-lacZ following treatment of cells for 15 h with
rapamycin (100 nM; RAP) or caffeine (10 mM; CAF). Relevant
genotypes are indicated.
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estimated half-life of 2.5–4.5 h) (Arnaud, 1987; Fredholm
et al., 1999). Assuming that caffeine inhibition of mTORC1
in vivo is comparable to its inhibition of yeast TORC1 in
vitro (Fig. 1D), moderate coffee consumption is expected
to cause a 4–8% inhibition of mTORC1 activity. This range
of inhibition compares well with the extent of inhibition that
we calculate to be necessary for lifespan extension in
yeast (~3%), and thus provides mechanistic support for
the correlative links between coffee consumption and lon-
gevity described above. At this concentration of caffeine,
inhibition of other PIKK family members (ATM, ATR,
DNA-PKcs) does not appear to have deleterious
consequences. Finally, caffeine has recently been shown
to suppress cell transformation (Nomura et al., 2005),
suggesting that, like rapamycin (Guertin and Sabatini,
2007), caffeine may also be a (well-tolerated) and effec-
tive anti-cancer agent.
Experimental procedures
Cloning and yeast experiments
Yeast strains and plasmids used in this study are listed in
Tables 1 and 2. Strains were grown at 30°C in standard rich
medium with 2% glucose (YPD) or synthetic medium with 2%
glucose (SD), 4% galactose (SGal) or 2% raffinose (SRaf) as
carbon source. Standard yeast genetic manipulations were
used. For site-directed mutagenesis, the QuickChange Site-
Directed Mutagenesis Kit (Stratagene) was used with the
Fig. 5. Caffeine extends yeast lifespan by downregulating the TORC1–Sch9–Rim15 signalling cascade.
A. Loss of Rim15 or expression of Sch92D3 reduces, while expression of Rim15S1061A extends lifespan. Survival (i.e. cfu ml-1) was assessed in
12-day-old cultures and expressed as relative values compared with wild-type cells.
B. Direct inhibition of TORC1 by low doses of caffeine and rapamycin extends chronological lifespan of S. cerevisiae wild type, but not of
rim15D cells. Each data point represents the mean of three samples. Survival data (cfu ml-1) are expressed as relative values compared with
the values at day 4 (early stationary phase). Survival curves for 0.4 mM caffeine (P = 0.0002) and 0.55 nM rapamycin (P = 0.0001) were
signiﬁcantly different from the untreated control curves as assessed by the Wilcoxon matched pairs test (using the GraphPad Prism 5.0
program).
Table 1. Strains used in this study.
Strain Genotype Source Figure
JK9-3da MATa; trp1, his4, ura3, leu2, rme1 Beck and Hall (1999)
IP11 MATa; rim15D::kanMX2 [JK9-3da] Pedruzzi et al. (2003) 3G, H
KT1960 MATa; ura3, leu2, his3, trp1, rme1 Pedruzzi et al. (2003)
IP31 MATa; rim15D::kanMX2 [KT1960] Pedruzzi et al. (2003) 3A, D
TB50a MATa; trp1, his3, ura3, leu2, rme1 Beck and Hall (1999) 3B, C, E
RL276-2d MATa; TRP1, HIS3, LEU2 [TB50] This study 1C
TB105-3b MATa; gat1::HIS3MX gln3::kanMX [TB50] Beck and Hall (1999) 1C
MP8 MATa; YPK2-6HA [HIS3MX] [TB50] This study 1B
TS120-2d MATa; sch9D::KanMX2 [TB50] Urban et al. (2007) 2A, B
RL194-4c MATa; TCO89-TAP[KlTRP1] 3HA-TOR1 [TB50] This study 1D, E
FD19 MATa; EGO1-myc Dubouloz et al. (2005) 3A
RL267-10d MATa; rim15D::kanMX2 [TB50] This study 2A, B; 4A
RL267-3d MATa; his4 sch9D::kanMX6, rim15D::KanMX2 [TB50] This study 3F; 4C
BY4741 MATa; his3D1, leu2D0, met15D0, ura3D0 Euroscarf
YFL033C MATa; rim15D::kanMX4 MET15 [BY4741] Euroscarf 5A, B
RL287-2A MATa; rim15D::kanMX4 MET15 [BY4741] This study 5B
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appropriate primers that introduced the mutations. The pres-
ence of mutagenized sites was conﬁrmed by sequencing.
Growth assay
TORC-bypass strains: wild type (RL276-2d + YCplac33),
TORC2-bypass [RL276-2d + YEp352(YPK2D239A-HA)],
TORC1-bypass (TB105-3b + pJU948 + YCplac33 + pRS414)
and TORC1/2-bypass [TB105-3b + pJU948 + YEp352
(YPK2D239A-HA) + pRS414] were grown to mid-log phase and
diluted to 0.25 OD600 in medium. Serial dilutions (1:1, 10, 100)
were spotted on YPD plates containing rapamycin or caffeine.
Plates were incubated 2–3 days at 30°C.
Sch9 and Ypk2 carboxy-terminal phosphorylation
To analyse Sch9-5HA C-terminal phosphorylation, TB50 cells
containing plasmids pJU450 and pJU676 were grown in
SC-Ura, -His, -Leu to mid-log phase, harvested and
re-suspended in YPAD + 0.2% Gln at 0.5 OD600. Cells were
grown for 60 min at 30°C prior to addition of medium contain-
ing rapamycin or caffeine and subsequent incubation for
another 30 min. Chemical fragmentation analysis was done
as described (Urban et al., 2007). To analyse Ypk2 phospho-
rylation, MP8 cells were grown in YPD + 0.2% glutamine
at 30°C to an OD600 between 0.6 and 0.8, at which point
rapamycin or caffeine was added to the indicated ﬁnal
concentration. Cells were shaken for an additional 30 min
and then harvested as described in Urban et al. (2007), but
without 2-nitro-5-thiocyanobenzoic acid (NTCB) cleavage.
Proteins were resolved by SDS-PAGE, transferred to nitro-
cellulose membrane and immunoblotted with anti-HA anti-
body or rabbit anti-phospho-T659 Ypk2 antiserum (this
antiserum detects both Sch9 phosphorylated at T737 by
TORC1 as well as Ypk2 phosphorylated at T659 by TORC2;
R. Loewith, unpublished).
TORC1 kinase assay
The TORC1 was puriﬁed from RL194-4c cells (grown to an
OD600 of 1.5–2.0 in YPD, 150 ml per assay point) using a
protocol very similar to that described (Urban et al., 2007).
To cleared protein extracts were added 25 ml of prepared
paramagnetic beads (Dynabeads M-270 Epoxy, 2 ¥ 109 ml-1,
coated with rabbit IgG; Sigma) and tubes were subsequently
rotated for 2 h at 4°C. Beads were collected by using a
magnet, washed extensively with cold lysis buffer without
inhibitors, aliquotted to 1.5 ml tubes and frozen at -80°C.
Kinase reactions were performed in a ﬁnal volume of 30 ml
containing TORC1-coupled beads, 600 ng Sch9 (Urban
et al., 2007), 25 mM Hepes/KOH pH 7.2, 50 mM KCl, 4 mM
MgCl2, 10 mM DTT, 0.5% Tween20, 1¥ Roche protease
inhibitor-EDTA, 100 mM ATP, 2 mCi [g-32P]-ATP and inhibitors
at various concentrations. In rapamycin experiments, each
reaction contained 200 ng of GST-FKBP12 and 1.1% DMSO.
Caffeine was dissolved in H2O and used at the indicated
concentrations. All assay points were done in triplicate.
Assays were started with addition of ATP, maintained at 30°C
for 15 min and terminated by the addition of 8 ml of 5¥ SDS-
PAGE buffer. Samples were heated to 95°C for 5 min; pro-
teins were resolved in SDS-PAGE, stained with Coomassie
and analysed using a Bio-Rad Molecular Imager. IC50 values
were calculated by using the GraphPad Prism 5.0 program.
Immunoprecipitation and immunoblot analyses
For co-IP experiments between Rim15 and Sch9, strain
KT1960 was co-transformed with pVW904 (expressing
Table 2. Plasmids used in this study.
Plasmid Vector; Insert Source Figure
pJU450 pRS415; TRP1, HIS3 Urban et al. (2007) 1A; 2A, B
pJU676 pRS416; SCH9-5HA Urban et al. (2007) 1A
pJU948 pRS415; SCH9-5HA (T723D, S726D, T737E, S758E, S765E) This study 1C
YEp352; YPK2D239A-HA YEp352; YPK2D239A-HA Kamada et al. (2005) 1C
pVW904 pYEplac181; TDH3p-RIM15-myc13 Wanke et al. (2005) 3A, H
pVW885 pCM189; MPK1-myc13 This study 3A
pVW881 pCM189; SCH9-2HA This study 3A
pVW995 pGEX3X; RIM15-KI Wanke et al. (2005) 3B, E
pTS130 YCplac33; SCH9-3HA Urban et al. (2007) 3B, E
pRL119-1 YCplac33; SCH9-3HA (K441A) Urban et al. (2007) 3B, E
pAH051 YCplac33; SCH9-3HA (T723D, S726D, T737E, S758E, S765E) Urban et al. (2007) 3B, C, E
pAH048 YCplac33; SCH9-3HA (T737E, S758E, S765E) This study 3B, E
pVW1313 pGEX3X; RIM15-aa1049–1078 This study 3C
pVW1327 pGEX3X; RIM15-aa1049–1078 (S1061A) This study 3C
pNB566 YEplac195; GAL1p-GST-RIM15 Wanke et al. (2005) 3D
pVW909 YEplac181; TDH3p-RIM15-myc (K823Y) This study 3F, G
pJU675 pRS416; SCH9 Urban et al. (2007) 3F, G; 4A–C
pJU841 pRS416; SCH9 (T723D, S726D, T737E, S758E, S765E) Urban et al. (2007) 3G; 4A–C; 5A
pFD633 pNP305; ADH1p-GFP-RIM15 (C1176Y) Pedruzzi et al. (2003) 4A, B
pVW1329 pNP305; ADH1p-GFP-RIM15 (C1176Y, S1061A) This study 4A, B
pVW1388 pRS315; RIM15 This study 4C; 5A; 5B
pVW1389 pRS315; RIM15 (S1061A) This study 4C; 5A
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Rim15-myc13 under control of the TDH3 promoter) and either
pVW881 or pVW885, which expresses Sch9-2HA or Mpk1-
2HA respectively, under the control of the tetO7 promoter. To
induce expression of the tetO7-controlled genes, cells were
grown for at least six generations in exponential growth
phase (OD600 < 1.0) in the absence of doxycycline. Subse-
quently, cells were lysed essentially as described (Wanke
et al., 2005) and HA-tagged proteins were puriﬁed from clari-
ﬁed extracts with the protein G-agarose IP kit (Roche Diag-
nostics GmbH) following the manufacturer instructions using
monoclonal mouse anti-HA antibodies (HA.11; Covance).
Bound proteins were eluted with sample buffer (5 min, 95°C)
and subjected to standard immunoblot analysis for detection
of co-precipitated Rim15-myc13 using anti-myc antibodies
(Myc-Tag 9B11; Cell Signaling). In parallel, strain FD19
(expressing a genomically myc13-tagged version of Ego1 and
harbouring plasmids pVW881 or pVW885) was subjected to
same treatment and served as a negative control.
GST pull-down and phospho-speciﬁc antibodies
Full-length Rim15 was puriﬁed from strain KT1960, which
expresses (from plasmid pNB566) GST-Rim15 under the
GAL1 promoter. Induction of GAL1-driven expression and
cell lysis were essentially performed as described (Wanke
et al., 2005). GST-tagged Rim15 was puriﬁed from clariﬁed
extracts using glutathione sepharose 4B beads (Amersham
Biosciences). Dephosphorylation of GST-Rim15 (bound to
sepharose 4B beads) was carried out by 30 min incubation
at 30°C with 1 U of l-phosphatase (Biolabs, NewEngland).
In control reactions, phosphatase inhibitors (10 mM NaF,
10 mM Na-orthovanadate, 10 mM p-NO2-phenylphosphate,
10 mM glycerophosphate and 10 mM Na-pyrophosphate)
were added. Antibodies against Rim15 phosphorylated on
Ser1061 were raised against a phosphorylated synthetic
peptide (A-S-L-R-R-S-E-pS-Q-L-S-F; where pS represents
phospho-Ser1061 of Rim15), adsorbed with the unphosphory-
lated form of the peptide, and affinity-puriﬁed with the phos-
phorylated peptide by Eurogentec.
Sch9 protein kinase assays and quantiﬁcation
of substrate phosphorylation
To assay in vitro phosphorylation of Rim15 by Sch9, TB50
cells containing plasmid-based alleles of SCH9-3HA were
grown and treated essentially as described (Urban et al.,
2007). Sch9 proteins were puriﬁed as described (Urban et al.,
2007). Kinase assays were performed with Sch9-3HA-bound
beads at 30°C for 30 min in kinase buffer (50 mM Tris-HCl
pH 7.5, 10 mM MgCl2, 1 mM DTT, 1 mM ATP and 10 mCi
ATP) and GST-Rim15-derived substrates (puriﬁed from
Escherichia coli ). Reactions were stopped by adding SDS
gel-loading buffer and boiling for 5 min and then subjected to
SDS-PAGE. Substrate phosphorylation levels were quanti-
ﬁed using a PhosphorImager (Cyclone Phosphor System;
PerkinElmer) and analysed with OptiQuant Image Analysis
software (Packard). Digital images of immunoblots were
acquired with a CanoScan LiDE scanner (Canon) and Pho-
toshop 7.0 (Adobe) and densitometric analysis of protein
bands was done with OptiQuant Image Analysis software.
Ageing assays
To analyse CLS, strain YFL033C was rendered prototroph
and co-transformed with plasmid-based alleles of RIM15
and SCH9. Accordingly, strains are: wild type (YFL033C +
pVW1388 + pRS413 + pRS416); rim15D (YFL033C +
pRS415 + pRS416 + pRS413; or strain RL287-2A + YEp195
in Fig. 5B); SCH92D3E (YFL033C + pVW1388 + pJU841 +
pRS413); RIM15S1061A (YFL033C + pVW1389 + pRS416 +
pRS413); and SCH92D3E/RIM15S1061A (YFL033C +
pVW1389 + pJU841 + pRS413) (see Table 1 for further
details). Cells were grown at 30°C in SD medium. Overnight
cultures were diluted to early exponential phase (0.2 OD600),
and rapamycin or caffeine (or drug vehicle alone) was added
during the exponential growth phase. Each experiment was
performed at least in triplicate. Cell cultures were incubated
at 30°C without replacing the growth medium throughout the
experiment. Culture aliquots were collected regularly and
serial dilutions were plated on YPD. Colony-forming units
(cfu ml-1) are expressed as percentage of the values at day 4
(early stationary phase).
Miscellaneous
For glycogen assays and b-galactosidase assays, strain
RL267-3d was co-transformed with plasmid-based alleles of
RIM15 and SCH9. Accordingly, strains are: wild type (RL267-
3d + pVW1388 + pJU675); rim15D (RL267-3d + pRS315 +
pJU675); SCH92D3E (RL267-3d + pVW1388 + pJU841);
RIM15S1061A (RL267-3d + pVW1389 + pJU675); and
SCH92D3E/RIM15S1061A (RL267-3d + pVW1389 + pJU841)
(see Table 1 for details). Cells were grown in SD medium to
exponential phase and then treated with 100 ng ml-1 rapamy-
cin or 10 mM caffeine or drug vehicle for 15 h at 30°C. Ten
OD600 equivalents of cells were harvested by ﬁltration onto
Millipore HA ﬁlters (Bedford, MA), placed upon a solid agar
matrix and exposed to iodine vapour for 2 min (Lillie and
Pringle, 1980). b-Galactosidase assays were performed as
described earlier (Reinders et al., 1998). Northern analyses
and immunoﬂuorescence were performed as described
(Dubouloz et al., 2005). DNA was stained with 4,6-diamidino-
2-phenylindole, which was added to the cultures (4 h prior to
ﬂuorescence microscopy) (Wanke et al., 2005) at a concen-
tration of 1 mg ml-1.
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